SCHEMBL379216

SCHEMBL379216

c1cnc2c(Nc3cccc4cccnc34)cccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 3/20 0.59
ALOX15 P16050 2/20 0.59
HTT P42858 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP1A2 P05177 1/20 0.59
MAPT P10636 4/20 0.58
TDP1 Q9NUW8 4/20 0.58
KDM4E B2RXH2 2/20 0.58
MMP2 P08253 2/20 0.58
TSHR P16473 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
GMNN O75496 1/20 0.58
LMNA P02545 1/20 0.58
TP53 P04637 1/20 0.58
HSP90AA1 P07900 1/20 0.58
CYP2D6 P10635 1/20 0.58
MMP9 P14780 1/20 0.58
NFKB1 P19838 1/20 0.58
MMP8 P22894 1/20 0.58
CCR1 P32246 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13337941 0.96 MEN1 (0.56) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL2939028 0.87 MEN1 (0.58) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL341142 0.86 SLC40A1 (0.62) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL27928520 0.85 KMT2A (0.66) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL2283401 0.83 KDR (0.56) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL2286768 0.83 TDP1 (0.52) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL31130165 0.83 CYP3A4 (0.61) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL7774451 0.83 CYP3A4 (0.61) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL17749155 0.83 GLO1 (0.56) GLO1ALOX15HTTCYP3A4CYP1A2
SCHEMBL4546341 0.83 TDP1 (0.62) GLO1ALOX15HTTCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US claimed
EP-1919894-A2 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF Palumed SA (FR) 2008-05-14 EP claimed
WO-2007015017-A2 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2007-02-08 WO claimed
EP-3549960-B1 PROCESS FOR POLYMERIZING AN OLEFIN MONOMER AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2021-03-24 EP disclosed
EP-3549960-B1 PROCESS FOR POLYMERIZING AN OLEFIN MONOMER AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2021-03-24 EP disclosed
EP-3549960-A1 PROCESS FOR POLYMERIZING AN OLEFIN MONOMER AND CATALYST THEREFOR Dow Global Technologies Llc (US) 2019-10-09 EP disclosed
EP-2536770-B1 PROCESS FOR POLYMERIZING AN OLEFIN MONOMER AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2019-06-05 EP disclosed
EP-2536770-B1 PROCESS FOR POLYMERIZING AN OLEFIN MONOMER AND CATALYST THEREFOR DOW GLOBAL TECHNOLOGIES LLC (US) 2019-06-05 EP disclosed
US-10184052-B2 Near infrared radiation-absorbing composition, near infrared radiation cut-off filter and production method therefor, and camera module and production method therefor FUJIFILM CORPORATION (JP) 2019-01-22 US disclosed
US-20180094086-A1 NEAR INFRARED ABSORBING COMPOSITION, NEAR INFRARED CUT FILTER, METHOD OF MANUFACTURING NEAR INFRARED CUT FILTER, DEVICE, METHOD OF MANUFACTURING COPPER-CONTAINING POLYMER, AND COPPER-CONTAINING POLYMER FUJIFILM CORPORATION (JP) 2018-04-05 US disclosed
US-20180094086-A1 NEAR INFRARED ABSORBING COMPOSITION, NEAR INFRARED CUT FILTER, METHOD OF MANUFACTURING NEAR INFRARED CUT FILTER, DEVICE, METHOD OF MANUFACTURING COPPER-CONTAINING POLYMER, AND COPPER-CONTAINING POLYMER FUJIFILM CORPORATION (JP) 2018-04-05 US disclosed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US disclosed
EP-1919894-A2 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF Palumed SA (FR) 2008-05-14 EP disclosed
US-7285518-B2 Dibenzo[b]perhydroheterocyclic amines and lubricating oil compositions CHEVRON ORONITE COMPANY LLC (US) 2007-10-23 US disclosed
EP-1801105-A1 Dibenzo[b]perhydroheterocyclic amines and lubricating oil compositions Chevron Oronite Company LLC (US) 2007-06-27 EP disclosed
US-20070142245-A1 Dibenzo[b]perhydroheterocyclic amines and lubricating oil compositions CHEVRON ORONITE COMPANY LLC 2007-06-21 US disclosed
WO-2007015017-A2 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2007-02-08 WO disclosed
US-6939969-B2 Tri-and bidentate amido ligands prepared by palladium0 coupling and metallation thereof to form metal-amido catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2005-09-06 US disclosed
US-20030032808-A1 Tri-and bidentate amido ligands prepared by palladium0 coupling and metallation threreof to form metal-amido catalysts CALIFORNIA INSTITUTE OF TECHNOLOGY 2003-02-13 US disclosed
WO-2002079207-A2 TRI-AND BIDENTATE AMIDO LIGANDS PREPARED BY PALLADIUM0 COUPLING AND METALLATION THEREOF TO FORM METAL-AMIDO CATALYSTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032808-A1 Tri-and bidentate amido ligands prepared by palladium0 coupling and metallation threreof to form metal-amido catalysts PUF60, PDCD10, HDAC10 GLO1 4360/4885ALOX15 3713/4885HTT 2578/4885
US-20070142245-A1 Dibenzo[b]perhydroheterocyclic amines and lubricating oil compositions ALOX12, ALOX15B, HRH1 GLO1 2785/4885ALOX15 6/4885HTT 78/4885
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF HTT, UBQLN2, UBQLN1 GLO1 1189/4885ALOX15 2801/4885HTT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.